Wall Street Bullish on AtaiBeckley (ATAI), Here’s Why

​AtaiBeckley Inc. (NASDAQ:ATAI) is one of the Best Penny Stocks That Will Skyrocket. Wall Street is bullish on AtaiBeckley Inc. (NASDAQ:ATAI) with analysts’ 12-month median price target reflecting more than 202% upside. Recently, on January 28, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock with a $15 price target. Earlier, Eddie Hickman from Guggenheim also initiated AtaiBeckley Inc. (NASDAQ:ATAI) with a Buy rating and a $11 price target.

​Hickman from Guggenheim noted that the company is a differentiated leader in next-generation psychiatry. The analyst also highlighted the recent merger with Beckley Psytech, which gives the company full ownership of BPL-003. BPL-003 is a lead asset that treats treatment-resistant depression and has shown compelling results in Phase IIIb efficacy and durability. The analyst believes that BPL-003 is strongly positioned for rapid clinical adoption and commercial scaling.

​Phase 2 trials of BPL-003 showed sustained MADRS score reductions, with 63% responder rates and 48% remission rates after a second dose. Moreover, Phase 3 trials are planned for Q2 2026 following FDA Breakthrough Therapy Designation.

​AtaiBeckley Inc. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company that researches, develops, and commercializes mental health treatments in the US, Germany, and Canada.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.